HRP20241574T1 - Metode za početak doziranja liječenja aripiprazolom - Google Patents
Metode za početak doziranja liječenja aripiprazolom Download PDFInfo
- Publication number
- HRP20241574T1 HRP20241574T1 HRP20241574TT HRP20241574T HRP20241574T1 HR P20241574 T1 HRP20241574 T1 HR P20241574T1 HR P20241574T T HRP20241574T T HR P20241574TT HR P20241574 T HRP20241574 T HR P20241574T HR P20241574 T1 HRP20241574 T1 HR P20241574T1
- Authority
- HR
- Croatia
- Prior art keywords
- aripiprazole
- depot formulation
- patient
- use according
- oral
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title claims 54
- 229960004372 aripiprazole Drugs 0.000 title claims 54
- 238000000034 method Methods 0.000 title claims 7
- 238000007918 intramuscular administration Methods 0.000 claims 29
- 238000009472 formulation Methods 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 27
- 238000002347 injection Methods 0.000 claims 24
- 239000007924 injection Substances 0.000 claims 24
- 238000012423 maintenance Methods 0.000 claims 4
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000007220 Cytochrome P-450 CYP2D6 Inhibitors Diseases 0.000 claims 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003544P | 2020-04-01 | 2020-04-01 | |
| EP21720012.0A EP4125903B1 (en) | 2020-04-01 | 2021-04-01 | Methods for dose initiation of aripiprazole treatments |
| PCT/JP2021/014194 WO2021201239A1 (en) | 2020-04-01 | 2021-04-01 | Methods for dose initiation of aripiprazole treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241574T1 true HRP20241574T1 (hr) | 2025-01-31 |
Family
ID=75581573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241574TT HRP20241574T1 (hr) | 2020-04-01 | 2021-04-01 | Metode za početak doziranja liječenja aripiprazolom |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US20230129919A1 (https=) |
| EP (3) | EP4467194A3 (https=) |
| JP (4) | JP7733000B2 (https=) |
| KR (3) | KR20220161402A (https=) |
| CN (3) | CN115379842A (https=) |
| AU (2) | AU2021248212A1 (https=) |
| BR (2) | BR112022018721A2 (https=) |
| CA (3) | CA3163321C (https=) |
| ES (1) | ES2995466T3 (https=) |
| HR (1) | HRP20241574T1 (https=) |
| HU (1) | HUE069157T2 (https=) |
| MX (2) | MX2022012354A (https=) |
| PL (1) | PL4125903T3 (https=) |
| TW (3) | TW202523329A (https=) |
| WO (2) | WO2021201238A1 (https=) |
| ZA (1) | ZA202210633B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| HUE069157T2 (hu) | 2020-04-01 | 2025-02-28 | Otsuka Pharma Co Ltd | Eljárások aripiprazol kezelések adagoláskezdésére |
| CA3197997A1 (en) | 2023-03-17 | 2025-01-23 | Otsuka Pharmaceutical Co., Ltd. | METHODS FOR DISPERSING INJECTABLE PREPARATIONS OF ARIPIPRAZOLE |
| CN120957722A (zh) | 2023-04-26 | 2025-11-14 | 大塚制药株式会社 | 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| UA82561C2 (uk) | 2003-10-23 | 2008-04-25 | Оцука Фармасьютикалз Ко., Лтд. | Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії |
| UA96342C2 (en) | 2007-06-25 | 2011-10-25 | Оцука Фармасьютикал Ко., Лтд. | Microspheres having core/shell structure |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| US10525057B2 (en) * | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
| EP4082546A1 (en) | 2017-05-16 | 2022-11-02 | Bow River LLC | Methods of treatment with cyp3a4 substrate drugs |
| EP3761983A1 (en) * | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN108498456B (zh) | 2018-05-16 | 2021-01-01 | 丽珠医药集团股份有限公司 | 一种阿立哌唑缓释微球及其制备方法 |
| CN110327296B (zh) | 2019-08-06 | 2021-10-22 | 深圳市泛谷药业股份有限公司 | 一种阿立哌唑长效注射制剂及其制备方法 |
| HUE069157T2 (hu) | 2020-04-01 | 2025-02-28 | Otsuka Pharma Co Ltd | Eljárások aripiprazol kezelések adagoláskezdésére |
-
2021
- 2021-04-01 HU HUE21720012A patent/HUE069157T2/hu unknown
- 2021-04-01 WO PCT/JP2021/014192 patent/WO2021201238A1/en not_active Ceased
- 2021-04-01 CN CN202180026022.3A patent/CN115379842A/zh active Pending
- 2021-04-01 KR KR1020227037400A patent/KR20220161402A/ko active Pending
- 2021-04-01 BR BR112022018721A patent/BR112022018721A2/pt unknown
- 2021-04-01 BR BR112022018647A patent/BR112022018647A2/pt unknown
- 2021-04-01 KR KR1020227037401A patent/KR102732030B1/ko active Active
- 2021-04-01 US US17/907,583 patent/US20230129919A1/en not_active Abandoned
- 2021-04-01 MX MX2022012354A patent/MX2022012354A/es unknown
- 2021-04-01 US US17/594,292 patent/US20220160621A1/en not_active Abandoned
- 2021-04-01 JP JP2022559750A patent/JP7733000B2/ja active Active
- 2021-04-01 EP EP24205231.4A patent/EP4467194A3/en active Pending
- 2021-04-01 EP EP21720011.2A patent/EP3941470A1/en active Pending
- 2021-04-01 JP JP2022559751A patent/JP7584535B2/ja active Active
- 2021-04-01 ES ES21720012T patent/ES2995466T3/es active Active
- 2021-04-01 TW TW113142852A patent/TW202523329A/zh unknown
- 2021-04-01 EP EP21720012.0A patent/EP4125903B1/en active Active
- 2021-04-01 TW TW110112185A patent/TWI906279B/zh active
- 2021-04-01 TW TW110112186A patent/TWI865760B/zh active
- 2021-04-01 PL PL21720012.0T patent/PL4125903T3/pl unknown
- 2021-04-01 CN CN202180025911.8A patent/CN115397420A/zh active Pending
- 2021-04-01 KR KR1020247038040A patent/KR20240165486A/ko active Pending
- 2021-04-01 AU AU2021248212A patent/AU2021248212A1/en active Pending
- 2021-04-01 CA CA3163321A patent/CA3163321C/en active Active
- 2021-04-01 HR HRP20241574TT patent/HRP20241574T1/hr unknown
- 2021-04-01 CA CA3212191A patent/CA3212191A1/en active Pending
- 2021-04-01 CN CN202411916296.1A patent/CN119792290A/zh active Pending
- 2021-04-01 WO PCT/JP2021/014194 patent/WO2021201239A1/en not_active Ceased
- 2021-04-01 AU AU2021245713A patent/AU2021245713A1/en active Pending
- 2021-04-01 MX MX2022012353A patent/MX2022012353A/es unknown
- 2021-04-01 CA CA3136727A patent/CA3136727A1/en active Pending
-
2022
- 2022-09-26 ZA ZA2022/10633A patent/ZA202210633B/en unknown
-
2023
- 2023-03-15 US US18/184,135 patent/US20230225962A1/en not_active Abandoned
-
2024
- 2024-06-03 US US18/732,392 patent/US20240374506A1/en active Pending
- 2024-11-05 JP JP2024193628A patent/JP2025020306A/ja active Pending
- 2024-11-26 US US18/959,760 patent/US20260115131A1/en active Pending
-
2025
- 2025-08-21 JP JP2025137577A patent/JP2025176037A/ja active Pending
- 2025-10-08 US US19/352,541 patent/US20260034053A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241574T1 (hr) | Metode za početak doziranja liječenja aripiprazolom | |
| Ciardiello et al. | A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor | |
| JP2018199733A5 (https=) | ||
| JP2011511072A5 (https=) | ||
| DK1390040T3 (da) | Farmaceutisk præparat til anvendelse i hormonerstatningsterapi | |
| JP2013509435A5 (https=) | ||
| JP2023520004A5 (https=) | ||
| IL95505A (en) | Neuro-peptide containing erection-inducing compositions and use thereof | |
| JP2004524278A5 (https=) | ||
| WO1998051290A2 (en) | Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent | |
| HRP20210624T1 (hr) | Režimi doziranja amisulprida za liječenje mučnine i povraćanja | |
| RU2014105288A (ru) | Способы и композиции для лечения астмы с использованием антител против il-13 | |
| HRP20240074T1 (hr) | Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem | |
| US8388963B2 (en) | Antitumor combinations containing a VEGF-inhibiting agent and 5FU or a derivative thereof | |
| HRP20240022T1 (hr) | Režim za doziranje propuštenih doza injektibilnih estera paliperidona s produljenim djelovanjem | |
| Taksande et al. | Agmatine inhibits behavioral sensitization to ethanol through imidazoline receptors | |
| WO2006050002A3 (en) | Compositions for controlled delivery of pharmaceutically active compounds | |
| Greer et al. | Bimekizumab-bkzx for the treatment of plaque psoriasis: A drug review | |
| Rosa et al. | Hippocampal cholinergic receptors and the mTOR participation in fear-motivated inhibitory avoidance extinction memory | |
| Song et al. | Differential Involvement of Central and Peripheral Norepinephrine in the Central Lipopolysaccharide‐Induced Interleukin‐6 Responses in Mice | |
| MX2021004551A (es) | Composicion farmaceutica para el tratamiento de la anemia aplasica. | |
| AU715260B2 (en) | TNF receptor and steroid hormone in a combined therapy | |
| JP2023500045A (ja) | Ｓｔｉｎｇアゴニストを用いたがんを処置する方法 | |
| Kissin et al. | Does midazolam inhibit the development of acute tolerance to the analgesic effect of alfentanil? | |
| MX2025012679A (es) | Inicio de dosis para el tratamiento de la esquizofrenia o el trastorno bipolar i con aripiprazol |